{"id":"W4403410377","doi":"10.1016/j.jtho.2024.09.074","title":"OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Samsung; Genentech; Humanitas Research Hospital; Universitair Ziekenhuis Antwerpen; Jewish General Hospital; Maastricht Universitair Medisch Centrum; Peter MacCallum Cancer Centre; Sungkyunkwan University; University of Manchester; Victoria University; University of Melbourne; Ottawa Hospital Research Institute; Monash University; Università degli Studi di Milano; Hospital de Câncer de Barretos; Seoul National University; Seoul National University Bundang Hospital; McGill University; Yale Cancer Center; Yale University","keywords":"Medicine; KRAS; Lung cancer; Oncology; Internal medicine; Phases of clinical research; Cancer; Cancer research; Clinical trial; Colorectal cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001420859,0.001152089,0.002444426,0.0004227528,0.0001796102,0.001376036,0.0005965169,0.0007050924,0.00223942],"category_scores_gemma":[0.001180719,0.0004407594,0.002590896,0.0006829576,0.0003497704,0.0007165601,0.0003073303,0.002193648,0.0005078355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008484974,"about_ca_system_score_gemma":0.0008700267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001308533,"about_ca_topic_score_gemma":0.005028526,"domain_scores_codex":[0.9996436,0.0001184335,0.00003184508,0.00007276688,0.00006108466,0.0000722475],"domain_scores_gemma":[0.999493,0.0001216911,0.0001689755,0.00002719297,0.00007349766,0.000115634],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4292486,0.005252124,0.03000574,0.005564507,0.01976001,0.0003916856,0.0002266617,0.005388072,0.02923337,0.000719,0.02370187,0.4505084],"study_design_scores_gemma":[0.5600024,0.1761224,0.164866,0.001227327,0.03492474,0.001684771,0.0003163194,0.004899496,0.006313075,0.001698674,0.04770754,0.0002372627],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8966715,0.08477617,0.001114183,0.002738216,0.0008722572,0.0009184453,0.005842105,0.0002104377,0.006856616],"genre_scores_gemma":[0.945007,0.03433508,0.001955981,0.003689463,0.0005128597,0.0006372677,0.01027657,0.00007096118,0.00351475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002444426,"threshold_uncertainty_score":0.007514298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01272044977152004,"score_gpt":0.3825332284158667,"score_spread":0.3698127786443466,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}